<DOC>
	<DOCNO>NCT02257242</DOCNO>
	<brief_summary>This study evaluate addition Vincristine Sulfate Liposome Injection ( Marqibo® ) standard regimen Bendamustine Rituximab adult patient indolent B-cell lymphoma . This dose-escalation study .</brief_summary>
	<brief_title>Vincristine Sulfate Liposome Injection ( Marqibo® ) , Bendamustine Rituximab—Phase I Trial Indolent B-cell Lymphoma</brief_title>
	<detailed_description>Bendamustine-rituximab standard chemotherapy regimen treatment many indolent B-cell lymphoma , patient experience recurrence lymphoma . Vincristine sulfate traditional component chemotherapy regimens non-Hodgkin lymphoma possible add bendamustine-rituximab regimen might provide good quality remission long duration remission acceptable toxicity . This phase 1 , single-center , open-label , single-arm trial patient indolent B-cell non-Hodgkin lymphoma otherwise appropriate bendamustine-rituximab initial subsequent line therapy . Patients receive rituximab bendamustine combination escalate dos vincristine sulfate liposome injection ( Marqibo® ) . The objective study ass safety combination establish maximum tolerate dose vincristine sulfate liposome injection ( Marqibo® ) combination .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm indolent Bcell nonHodgkin lymphoma . Radiological measurable disease . Previous treatment lymphoma allow , exception use bendamustine within 6 month prior use vincristine sulfate liposome injection Eastern Cooperative Oncology Group performance status 0 1 ; Life expectancy least 6 month ; Adequate organ marrow function ; Women childbearing potential men must agree use adequate contraception . Ability understand willingness sign write informed consent document . History allergic reaction attribute drug use study . Any lymphomadirected therapy within 4 week . Any prior treatment vincristine sulfate liposome injection . Prior treatment bendamustine vincristine sulfate within 180 day enrollment . Patients receive investigational agent . Central nervous system involvement . Peripheral sensory motor neuropathy . History demyelinate condition . Positive test Human AntiChimeric Antibody ( HACA ) . Patients receive medication substance strong inhibitor inducer Cytochrome P450 , family 3 , subfamily A ( CYP3A ) enzyme ineligible . Uncontrolled intercurrent illness . Prisoners . Pregnant breastfeed woman . Known Human Immunodeficiency Virus ( HIV ) active Hepatitis B infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bendamustine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Vincristine sulfate</keyword>
	<keyword>Vincristine sulfate liposome injection</keyword>
	<keyword>Phase I</keyword>
	<keyword>Escalation With Overdose Control</keyword>
</DOC>